Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 36 | 2025 | 293 | 8.780 |
Why?
|
| Oropharyngeal Neoplasms | 34 | 2025 | 165 | 8.630 |
Why?
|
| Carcinoma, Squamous Cell | 30 | 2024 | 669 | 3.340 |
Why?
|
| Human papillomavirus 16 | 18 | 2025 | 49 | 3.270 |
Why?
|
| Papillomaviridae | 18 | 2023 | 143 | 2.510 |
Why?
|
| Alphapapillomavirus | 5 | 2022 | 30 | 2.000 |
Why?
|
| DNA, Viral | 6 | 2025 | 480 | 1.730 |
Why?
|
| Head and Neck Neoplasms | 17 | 2024 | 502 | 1.710 |
Why?
|
| Antibodies, Viral | 6 | 2025 | 1151 | 1.490 |
Why?
|
| Oncogene Proteins, Viral | 4 | 2025 | 58 | 1.320 |
Why?
|
| Papillomavirus Vaccines | 5 | 2022 | 94 | 1.240 |
Why?
|
| Anus Neoplasms | 3 | 2022 | 38 | 1.110 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2022 | 237 | 1.080 |
Why?
|
| Smoking | 11 | 2023 | 1045 | 0.930 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 35 | 0.920 |
Why?
|
| Sexual Behavior | 4 | 2018 | 247 | 0.850 |
Why?
|
| Mouth Diseases | 1 | 2023 | 11 | 0.850 |
Why?
|
| Early Detection of Cancer | 5 | 2025 | 360 | 0.760 |
Why?
|
| Alcohol Drinking | 6 | 2016 | 343 | 0.730 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 33 | 0.730 |
Why?
|
| Middle Aged | 46 | 2025 | 26867 | 0.720 |
Why?
|
| Mouth Neoplasms | 7 | 2023 | 84 | 0.710 |
Why?
|
| Biomarkers, Tumor | 4 | 2025 | 1492 | 0.660 |
Why?
|
| Health Care Costs | 3 | 2020 | 371 | 0.660 |
Why?
|
| Condylomata Acuminata | 1 | 2018 | 15 | 0.620 |
Why?
|
| Case-Control Studies | 17 | 2023 | 3287 | 0.600 |
Why?
|
| Microbiota | 1 | 2023 | 388 | 0.590 |
Why?
|
| Male | 49 | 2025 | 61375 | 0.590 |
Why?
|
| Mouth | 1 | 2018 | 61 | 0.570 |
Why?
|
| Cancer Survivors | 1 | 2020 | 209 | 0.560 |
Why?
|
| Humans | 65 | 2025 | 124867 | 0.470 |
Why?
|
| Prognosis | 13 | 2024 | 4631 | 0.450 |
Why?
|
| Vaccination | 2 | 2018 | 955 | 0.450 |
Why?
|
| Female | 49 | 2024 | 66655 | 0.440 |
Why?
|
| Neoplasm Staging | 8 | 2016 | 1278 | 0.430 |
Why?
|
| Aged | 30 | 2024 | 19825 | 0.410 |
Why?
|
| Laryngeal Neoplasms | 3 | 2020 | 80 | 0.370 |
Why?
|
| Prospective Studies | 7 | 2024 | 6148 | 0.370 |
Why?
|
| Prevalence | 8 | 2023 | 2448 | 0.350 |
Why?
|
| Sex Distribution | 5 | 2019 | 303 | 0.330 |
Why?
|
| Age Distribution | 5 | 2018 | 415 | 0.320 |
Why?
|
| Risk Factors | 18 | 2023 | 10281 | 0.310 |
Why?
|
| Texas | 8 | 2021 | 3586 | 0.290 |
Why?
|
| Insurance, Health | 2 | 2019 | 138 | 0.290 |
Why?
|
| Medicaid | 2 | 2019 | 242 | 0.270 |
Why?
|
| Reference Values | 5 | 2017 | 710 | 0.260 |
Why?
|
| Incidence | 9 | 2020 | 3138 | 0.260 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 470 | 0.250 |
Why?
|
| Logistic Models | 4 | 2017 | 1811 | 0.240 |
Why?
|
| Adult | 23 | 2024 | 29562 | 0.240 |
Why?
|
| Age Factors | 3 | 2020 | 2822 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 509 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 5 | 2019 | 1585 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1327 | 0.230 |
Why?
|
| Cohort Studies | 7 | 2017 | 4805 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2022 | 3152 | 0.220 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2018 | 129 | 0.220 |
Why?
|
| Smokers | 2 | 2020 | 39 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2022 | 16336 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 5163 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 824 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 1053 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2022 | 2635 | 0.210 |
Why?
|
| Anus Diseases | 1 | 2022 | 12 | 0.210 |
Why?
|
| Vulvar Neoplasms | 1 | 2022 | 18 | 0.200 |
Why?
|
| Cotinine | 3 | 2008 | 23 | 0.200 |
Why?
|
| Proportional Hazards Models | 5 | 2024 | 1358 | 0.200 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 71 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1148 | 0.190 |
Why?
|
| Polymorphism, Genetic | 5 | 2016 | 812 | 0.190 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 367 | 0.190 |
Why?
|
| Mouthwashes | 1 | 2021 | 10 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 2 | 2013 | 152 | 0.180 |
Why?
|
| Pharyngeal Neoplasms | 3 | 2008 | 26 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 3435 | 0.180 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 19 | 0.180 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2020 | 15 | 0.170 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 183 | 0.170 |
Why?
|
| Sex Factors | 3 | 2018 | 1286 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 71 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2018 | 835 | 0.170 |
Why?
|
| Smoking Cessation | 2 | 2020 | 198 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2020 | 61 | 0.170 |
Why?
|
| Direct Service Costs | 1 | 2019 | 8 | 0.160 |
Why?
|
| United States | 7 | 2020 | 10906 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2020 | 286 | 0.160 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 2 | 0.160 |
Why?
|
| Capsid Proteins | 2 | 2018 | 184 | 0.160 |
Why?
|
| Oropharynx | 2 | 2013 | 34 | 0.160 |
Why?
|
| DNA-Binding Proteins | 4 | 2015 | 2043 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 101 | 0.160 |
Why?
|
| Anal Canal | 1 | 2019 | 81 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 307 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 46 | 0.150 |
Why?
|
| Cause of Death | 1 | 2020 | 474 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2003 | 815 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2017 | 3448 | 0.150 |
Why?
|
| Mass Screening | 2 | 2022 | 783 | 0.150 |
Why?
|
| Odds Ratio | 4 | 2016 | 1257 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2024 | 1562 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2024 | 1507 | 0.140 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1997 | 19 | 0.140 |
Why?
|
| Alcohols | 1 | 1997 | 18 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 555 | 0.140 |
Why?
|
| Lymphocytes | 3 | 2016 | 408 | 0.140 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1997 | 135 | 0.140 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 231 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 681 | 0.130 |
Why?
|
| Young Adult | 4 | 2020 | 9047 | 0.130 |
Why?
|
| Genes, p16 | 1 | 2016 | 13 | 0.130 |
Why?
|
| Fungal Proteins | 1 | 1997 | 129 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 270 | 0.130 |
Why?
|
| Recombinational DNA Repair | 1 | 2016 | 16 | 0.130 |
Why?
|
| Genotype | 8 | 2022 | 2557 | 0.130 |
Why?
|
| DNA Repair | 3 | 2005 | 585 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2018 | 472 | 0.130 |
Why?
|
| RNA Helicases | 1 | 2015 | 63 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 19336 | 0.120 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 31 | 0.120 |
Why?
|
| Apoptosis | 2 | 2016 | 1796 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 274 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1997 | 429 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 91 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1691 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2051 | 0.110 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 42 | 0.110 |
Why?
|
| Extremities | 1 | 2013 | 83 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 53 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 29 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 147 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 899 | 0.100 |
Why?
|
| Survival Rate | 3 | 2024 | 2060 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 870 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 304 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2010 | 285 | 0.090 |
Why?
|
| Biomarkers | 1 | 2020 | 3069 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 239 | 0.090 |
Why?
|
| Sarcoma | 1 | 2013 | 183 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2023 | 1397 | 0.090 |
Why?
|
| Time Factors | 1 | 2020 | 6319 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 79 | 0.080 |
Why?
|
| Medical History Taking | 1 | 2010 | 108 | 0.080 |
Why?
|
| Binding Sites | 3 | 2018 | 1295 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 135 | 0.080 |
Why?
|
| Disease Progression | 1 | 2015 | 2058 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 777 | 0.080 |
Why?
|
| Codon | 1 | 2008 | 97 | 0.070 |
Why?
|
| Dronabinol | 1 | 2008 | 30 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2008 | 122 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 50 | 0.070 |
Why?
|
| Carcinogens | 1 | 2008 | 152 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 76 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2008 | 127 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12398 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2008 | 204 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2096 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2020 | 217 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 295 | 0.060 |
Why?
|
| Gastrostomy | 1 | 2005 | 85 | 0.060 |
Why?
|
| G2 Phase | 1 | 2004 | 44 | 0.060 |
Why?
|
| Gamma Rays | 1 | 2004 | 49 | 0.060 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2004 | 55 | 0.060 |
Why?
|
| Registries | 1 | 2010 | 1430 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1685 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2003 | 19 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 723 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 419 | 0.050 |
Why?
|
| State Medicine | 1 | 2022 | 12 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2815 | 0.050 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2022 | 5 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2022 | 14 | 0.050 |
Why?
|
| Endonucleases | 1 | 2002 | 53 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 287 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 190 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 116 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 293 | 0.050 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2001 | 18 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 754 | 0.050 |
Why?
|
| Vagina | 1 | 2022 | 194 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2002 | 231 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6583 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2020 | 12 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 759 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1439 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 119 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 288 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 47 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 249 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 202 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 1599 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 241 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1997 | 88 | 0.030 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2016 | 16 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 1036 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1997 | 161 | 0.030 |
Why?
|
| Glycerol | 1 | 1997 | 97 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 73 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1997 | 292 | 0.030 |
Why?
|
| Viral Core Proteins | 1 | 2016 | 22 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 9 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1884 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 345 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2002 | 1497 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 163 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 1319 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1179 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 810 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 1263 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2016 | 131 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 1323 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 798 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2881 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 570 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2016 | 381 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 502 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 144 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1392 | 0.030 |
Why?
|
| Genome | 1 | 2016 | 472 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 167 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1288 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 364 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2002 | 2582 | 0.020 |
Why?
|
| Base Sequence | 1 | 1997 | 3090 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1240 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 3877 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1943 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3039 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3343 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1092 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2154 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 130 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 143 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 125 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 696 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1686 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 14018 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 388 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2002 | 21 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 797 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 70 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 301 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1613 | 0.010 |
Why?
|
| Child | 1 | 2019 | 24399 | 0.010 |
Why?
|
| Alcoholism | 1 | 2001 | 231 | 0.010 |
Why?
|
| Comorbidity | 1 | 2001 | 1532 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 3728 | 0.010 |
Why?
|